Exchange: NASDAQ·Updated 02:05 PM EDT
RPRX logo

RPRXRoyalty Pharma plc - Ordinary Shares - Class A

$55.95
$0.28
(0.50%)
Today
EarningsAug 5
Mkt Cap$32.06B
Vol1.14M
News
all
press releases
Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks
News Placeholder
More News
News Placeholder
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice
Does Royalty Pharma (RPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
News Placeholder
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?
Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
News Placeholder
RPRX or ACAD: Which Is the Better Value Stock Right Now?
RPRX vs. ACAD: Which Stock Is the Better Value Option?
Zacks
News Placeholder
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
Zacks
News Placeholder
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance...
Yahoo! Finance: News
News Placeholder
Royalty Pharma Q1 Profit, Revenue Increase; Raises Full-year Portfolio Receipts Outlook
(RTTNews) - Royalty Pharma plc (RPRX) on Thursday reported higher first-quarter earnings, supported mainly by growth in income from financial royalty assets...
Nasdaq News: Markets
News Placeholder
Royalty Pharma Q1 Earnings Call Highlights
Royalty Pharma (NASDAQ:RPRX) reported what executives described as a "strong start" to 2026, driven by double-digit growth in cash receipts, active capital deployment and a series of clinical and regulatory developments across its portfolio, according to management's remarks on the company's first-q...
MarketBeat
News Placeholder
RPRX vs. AMGN: Which Stock Is the Better Value Option?
RPRX vs. AMGN: Which Stock Is the Better Value Option?
Zacks
<
1
2
...
>

Advertisement|Remove ads.